Trial Profile
An Access Protocol for Continued Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody Radiolabeled With 1-125 for High Grade Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-EGFR monoclonal antibody 425 (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 24 Mar 2011 New trial record